DOB

DOB, or 2,5-dimethoxy-4-bromoamphetamine, is a synthetic psychedelic amphetamine in the DOx family. It has a bromine atom at the 4-position of the phenyl ring and methoxy groups at the 2- and 5-positions. DOB acts primarily through serotonin 5-HT_2A receptors and is known for a long-lasting psychedelic effect. Clinical reports include prolonged coma, seizures, metabolic acidosis and fatal overdose.

Chemistry and history

DOB is the alpha-methylated amphetamine counterpart of 2C-B. The additional alpha-methyl group distinguishes it from the two-carbon phenethylamine structure of 2C-B and contributes to the different pharmacokinetic profile of the DOx series.

DOB was described in the work of Alexander Shulgin and later appeared in illicit markets, sometimes on blotter paper or in products represented as LSD. Because the compound is long acting, the effects may continue well beyond the period associated with many other psychedelics.

Pharmacology

DOB acts as a serotonergic psychedelic, with agonist activity at the 5-HT_2A receptor. Its effects are similar in broad terms to other hallucinogenic amphetamines such as DOM and DOC. The alpha-methyl group changes its metabolism compared with the corresponding 2C phenethylamine.

Research on 2,5-dimethoxy amphetamines has examined their distribution and metabolism in animals and biological samples. These studies aid forensic detection, without fully explaining DOB’s pharmacokinetics in humans.

Subjective effects

The PsychonautWiki profile of DOB describes long-lasting visual changes, altered cognition and stimulation as part of the psychedelic experience. Historical reports describe intense perceptual effects, but there are few controlled human studies.

Visual and cognitive effects

Reports include geometric visual patterns, changes in colour and depth perception, altered time perception and intensified thought processes. Emotional effects may include euphoria or anxiety. Confusion, agitation and difficulty sleeping have also been described.

Physical effects

Physical effects reported in clinical and historical accounts include nausea, vomiting, increased heart rate, elevated blood pressure, agitation and muscle tension. Severe intoxication can involve seizures, loss of consciousness and prolonged coma.

Clinical toxicity

A forensic report described two men who developed intense hallucinations and vomiting after exposure to DOB. Both became unconscious and remained in deep coma for several days. One survived, while the other developed convulsions and metabolic acidosis and died six days later. Toxicological analysis confirmed DOB in both cases (Balíková, 2005).

The case series demonstrates that severe and fatal poisoning can occur. It does not establish a concentration threshold that predicts outcome, and the number of published cases remains small.

Toxicity and research limitations

DOB has a more established clinical toxicity record than many obscure psychedelic amphetamines, but controlled human safety data remain limited. Severe cases have involved prolonged unconsciousness, seizures and metabolic complications. The long duration of action can complicate clinical management, particularly when the identity of a product is uncertain.

Its dependence potential has not been characterised in controlled human studies. As with other serotonergic psychedelics, physical dependence is not considered a defining feature, but this does not imply that acute exposure is safe.

Related compounds

DOB is related to DOC, DOI and DOM, which are also psychedelic amphetamines. It is the amphetamine counterpart of 2C-B.